Ventripoint Diagnostics and Providence Health Care Ventures Announce Collaboration to Validate AI-Enabled Cardiac Imaging at St. Paul's Hospital

(TheNewswire)

Study to evaluate potential toreduce cardiac MRI demand and expand access to advanced heartdiagnostics across care settings

Toronto, Ontario – TheNewswire - October 29, 202 5 - VentripointDiagnostics Ltd. (" Ventripoint " or the " Company "),(TSXV:VPT; OTC:VPTDF) today announced it has entered into acollaboration with Providence Health Care Ventures (“PHCVentures”) to validate the Company’s VMS+™ platform at St.Paul’s Hospital in Vancouver, British Columbia. The collaboration will evaluate how artificialintelligence-enhanced echocardiography may reduce dependence oncardiac MRI by providing accurate cardiac measurements earlier in thediagnostic pathway, with the potential for a subset of patients toavoid MRI entirely.

Cardiac MRI is widely regarded as the gold standard foraccurate heart volume and function measurements, but limitedavailability and long wait times can delay treatment decisions.VMS+™ uses artificial intelligence to generate 3-D heart models fromstandard 2-D echocardiography images and has demonstrated clinicalagreement with MRI-derived measurements in previously publishedevaluations. The platform is FDA-cleared and Health Canada-licensedand operates on existing 2D ultrasound systems, allowing healthsystems to increase advanced imaging capacity without capitalacquisition of new scanners.

Building on Prior ClinicalEvidence

VMS+™ has been implemented at sites including theHospital for Sick Children (Toronto), the Peter Munk Cardiac Centre(University Health Network, Toronto) and evaluated in clinical studiesat Mayo Clinic, where echo-derived measurements using VMS+™ wereshown to closely align with cardiac MRI. A poster recently presentedat the British Society of Echocardiography 2025 conferencedemonstrated that VMS+™ used for longitudinal assessment of adultcongenital heart defect patients generated results comparable to MRIand more accurate than 3D echocardiography.

The collaboration with PHC Ventures aims to validateVMS+™ performance within real-world workflows at St. Paul’sHospital - one of Western Canada’s leading cardiac programs - bycomparing VMS+™ derived measurements from echocardiography withcardiac MRI, and by evaluating workflow integration, potentialreductions in MRI referrals, impact on wait times, and associatedsystem-level cost efficiencies.

“This technology helps identify which patients trulyneed an MRI and which can be safely assessed using a standardechocardiogram,” said Brian Simmers, President of PHC Ventures.“By doing so, we can reduce MRI wait times, lower costs, and providefaster access to high-quality cardiac care.”

“MRI remains the gold standard for cardiac imaging,but it is not always within reach for every patient,” said Dr.Robert Moss, Physician Lead, Echocardiography, St. Paul’s Hospital.“The promise of AI-enhanced echocardiography like VMS+™ is that itcould bring MRI-level precision to a more accessible modality. Thatmeans faster diagnoses, more timely treatment decisions, and improvedpatient outcomes — especially in communities where access toadvanced imaging is limited.”

Enabling Access Beyond MajorCentres

By augmenting conventional ultrasound infrastructure,VMS+™ has the potential to extend advanced cardiac diagnostics torural and Indigenous communities, where MRI access is constrained andpatient travel distances are significant. AI-enhanced echocardiographyat the point-of-care may reduce avoidable transfers, support ongoingmonitoring in local settings, and contribute to more equitable accessto advanced imaging.

“Our vision is to make high-quality cardiac imagingavailable wherever an echo machine exists,” said Hugh MacNaught,President and CEO of Ventripoint. “Partnering with PHC Ventures andthe St. Paul’s cardiac team enables validation in a leading cardiaccentre and creates a pathway to demonstrate health-system impactacross settings - from tertiary hospitals to remotecommunities.”

The collaboration is expected to commence in November2025, with implementation beginning in early 2026.

About Ventripoint DiagnosticsLtd.

Ventripoint is an industry leaderin the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary Knowledge Based Reconstruction technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all of Ventripoint's productsthat guide our future developments. In addition, VMS+ is versatile andcan be used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe, and Canada.

About Providence Health CareVentures

PHC Ventures is the commercialization arm of ProvidenceHealth Care. The group enables the validation and deployment of healthinnovations by providing access to clinical environments, domainexpertise, and collaboration within Providence’s hospital network,including St. Paul’s Hospital and the new Clinical Support andResearch Centre.

For further information, pleasecontact:

Hugh MacNaught

hmacnaught@ventripoint.com

604-671-4201

Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.

Forward Looking Statements

This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' andsimilar expressions are intended to identify forward-lookinginformation or statements. The forward-looking statements andinformation are based on certain key expectations and assumptions madeby the Company. Although the Company believes that the expectationsand assumptions on which such forward-looking statements andinformation are based are reasonable, undue reliance should not beplaced on the forward-looking statements and information because theCompany can give no assurance that they will prove to becorrect.

Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company'smost recent annual management's discussion and analysis that isavailable on the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.

Copyright (c) 2025 TheNewswire - All rights reserved.